Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + Trametinib in Japanese BRAF V600E NSCLC
NCT02672358Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Sep 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoint: Overall Response Rate at 2 years. Planned start Sep 2018; status: withdrawn.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02672358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672358.